GlaxoSmithKline Announces US Filing For Mepolizumab

FeaturesDow Jones Newswires

GlaxoSmithKline PLC (GSK.LN) Wednesday announced a regulatory submission for mepolizumab, used to treat the rare disease Eosinophilic Granulomatosis with Polyangiitis, to be made available in the U.S.

Shares at 1516GMT, down 34 pence, or 2%, at 1,664 pence valuing the company at GBP81.86 billion.

Continue Reading Below

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

June 28, 2017 11:32 ET (15:32 GMT)